Loading organizations...
Loading organizations...
Seahorse Bioscience has raised $20.0M across 3 funding rounds.
Seahorse Bioscience has raised $20.0M in total across 3 funding rounds.
Seahorse Bioscience is a technology company specializing in the development and manufacture of advanced analytical instruments and consumables for measuring cellular bioenergetics, primarily serving the life sciences, pharmaceutical, and biotechnology research sectors. Its flagship product, the Seahorse XF Extracellular Flux Analyzer, enables real-time, non-invasive measurement of cellular metabolism by simultaneously assessing mitochondrial respiration and glycolysis in live cells. This technology addresses critical needs in drug discovery and biological research by providing precise insights into cellular energy production and metabolic dysfunction, supporting studies in areas such as mitochondrial diseases, cancer, and metabolic disorders. Since its founding, Seahorse Bioscience has demonstrated strong growth and global adoption, becoming a standard tool in metabolic assays worldwide before being acquired by Agilent Technologies in 2016[2][3][5].
Seahorse Bioscience was founded in 2001 by Jay Teich, Andy Neilson, and Jim Orrell, with a vision to simplify and enhance cellular metabolic measurements. The company emerged from the need for more efficient and physiologically relevant assays to study cell metabolism, leading to the development of the innovative XF technology introduced in 2006. Early traction came from the adoption of their extracellular flux technology, which combined electro-optical instrumentation with proprietary plastic cartridges to enable multi-well, real-time metabolic profiling. This breakthrough positioned Seahorse as a leader in cellular bioenergetics, culminating in its acquisition by Agilent Technologies, which expanded its global reach and integrated it into a broader portfolio of life science tools[2][5][8].
Seahorse Bioscience rides the growing trend of metabolic and mitochondrial research, which is increasingly recognized as fundamental to understanding diseases such as cancer, neurodegeneration, diabetes, and immune disorders. The timing is critical as the life sciences sector shifts toward functional, real-time cellular assays that provide dynamic insights beyond static molecular measurements. Market forces favor technologies that enable precision medicine and drug discovery by elucidating cellular energy pathways. Seahorse’s technology influences the broader ecosystem by enabling researchers to link metabolism to disease mechanisms, accelerating therapeutic development and biomarker discovery globally[3][4].
Looking ahead, Seahorse Bioscience, under Agilent’s umbrella, is poised to expand its impact by integrating with emerging technologies such as single-cell analysis, artificial intelligence for data interpretation, and multi-omics platforms. Trends in personalized medicine and metabolic therapeutics will likely drive demand for more sophisticated, high-throughput metabolic profiling tools. Seahorse’s influence is expected to grow as cellular bioenergetics becomes a routine part of drug development pipelines and academic research, further solidifying its role as a foundational technology in life sciences. Continued innovation in assay design, automation, and global accessibility will be key to maintaining its leadership position[3][6].
Seahorse Bioscience has raised $20.0M in total across 3 funding rounds.
Seahorse Bioscience's investors include Collaborative Seed & Growth Partners, Foundry Group, Long Journey Ventures, Speedy Packets Inc., David Cancel, Dharmesh Shah, EQT Life Sciences, Flagship Pioneering.
Seahorse Bioscience has raised $20.0M across 3 funding rounds. Most recently, it raised $9.0M Venture Round in May 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2012 | $9.0M Venture Round | Collaborative Seed & Growth Partners, Foundry Group, Long Journey Ventures, Speedy Packets Inc., David Cancel, Dharmesh Shah | |
| Mar 1, 2010 | $5.0M Series D | EQT Life Sciences | |
| Mar 1, 2009 | $6.0M Series D | Flagship Pioneering |
